Tarsa Therapeutics Reports Positive Results From Phase II Trial of Its Oral Calcitonin in Prevention of Post-Menopausal Osteoporosis
10/16/2012 9:27:42 AM
More...
|
Tarsa Therapeutics' Drug Successful in Prevention of Post-Menopausal Osteoporosis
10/16/2012 6:54:54 AM
More...
|
Tarsa Therapeutics to Assist Therapicon in Its Challenge to CHMP's Recommendation to Limit Use of Calcitonin
10/12/2012 10:54:55 AM
More...
|
Tarsa Therapeutics Signs Commercial Supply Agreement for its Ostora(TM) Oral Calcitonin Product With QS Pharma
3/21/2012 10:44:03 AM
More...
|
Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin
3/16/2012 6:27:25 AM
More...
|
Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA(TM) Oral Calcitonin
12/13/2011 11:11:52 AM
More...
|
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
9/19/2011 10:48:27 AM
More...
|
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase 3 Osteoporosis Treatment Trial
9/19/2011 6:27:18 AM
More...
|
Tarsa Therapeutics Raises $24.5 Million, Advances Its Oral Calcitonin for the Treatment and Prevention of Postmenopausal Osteoporosis
7/12/2011 6:56:48 AM
More...
|
Unigene Laboratories, Inc. (UGNE)’s Oral Peptide Drug Delivery Technology Validated with Positive Top-Line Phase 3 Results from Tarsa Therapeutics’s ORACAL Trial of Oral Calcitonin
3/24/2011 6:21:33 AM
More...
|
|